SIMPLAAFY backs simpler Watchman regimens, and Blackstone put $455M behind BSX's pump.
Regeneron rose 13.3% on the quarter, and both Friday biotech IPO debuts broke.
Lilly raised its year to $91 to 92 billion, and Merck's quarter passed the week's test.
Boston Scientific cut guidance a third time, and Biogen returned to growth and fell 3.4%.
Savolitinib made the NEJM, Novartis raised its year, and BioNTech's HER2 ADC won small.
Amgen got paid for a new standard, Summit did not, and Anthropic filed to IPO.
Divarasib beat the approved KRAS drugs head to head, Moderna fell on a win, and Lycia debuted up 66.7%.
The FDA cleared Ultomiris in IgA nephropathy, Biohaven's ataxia drug got a second review, and QIAGEN's first session was quiet.
Abbott is splitting in two, EQT is taking QIAGEN private at a 40 percent premium, and brepocitinib swept both Phase 3 uveitis trials.
GSK landed the first finite course functional cure option in hepatitis B, Disc raised $450 million overnight, and Alcon paid $550 million for Neurotech.
Roche licensed Hansoh's ADC engine without buying it, Merck KGaA bought Silence outright, and Disc and Veradermics both won Phase 3.
Medtronic completed its exit, China proposed platform export bans, City closed its debut up 24.4%, and the CHMP backed the first oral GLP-1 pill in the EU.
City priced an upsized $200 million IPO, Iambic closed up 18.2%, AstraZeneca signed insitro, and the week's clearing prices got their grade.
Anktiva clears by extrapolation, MiniMed's exchange closes at 18.3%, and the market grades Liquidia's peace and Biomea's pitch in one session.
J&J beat and raised and still fell, Liquidia ends the United Therapeutics war, and the IPF field sorts itself in one week.
A celiac drug class arrives, Bristol Myers withholds its numbers, and MiniMed's exchange runs five to one.
BRUNELLO's full table, three Friday approvals, a $1.1 billion close, and two Monday morning binaries.
A Phase 3 futility stop, a celiac win from a $2.2B bet, Viatris' $1.65B revenue deal, and the week's grade.
PhRMA took GLOBE to court, Caribou wound down for lack of funding, and Cerevance rescued its Parkinson's pill in Phase 3.
Firmonertinib missed its first line primary endpoint, Vaxcyte priced $1 billion a day after its rally, and the week's premium curve got its proof.
VAX-31 met every primary endpoint in its pivotal Phase 3, and four buyers paid up across the succession curve in a single day.
Novartis took Abogen's mRNA engager, CSL took Alentis' claudin-1 antibody, and the premium keeps flowing to clinical proof.
Regeneron kept the muscle at 52 weeks, survodutide met every endpoint and missed the bar, and Sanofi paid $1 billion to succeed Dupixent with its own targets.
EloraTZP cut weight 23.3% in Phase 2, Foundayo passed its cardiovascular safety test, and CMS finalized international pricing for Medicare Part B.
Lilly's triple agonist cut weight 20.8% in Phase 3, uniQure's Huntington's benefit weakened at 48 months, and Beam sued two rivals over base editing.
